Dasatinib Patent Expiration
Dasatinib is Used for treating protein tyrosine kinase-associated disorders and various types of cancer, including chronic myelogenous leukemia. It was first introduced by Bristol Myers Squibb Co
Dasatinib Patents
Given below is the list of patents protecting Dasatinib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Phyrago | US11202778 | Amorphous solid dispersions of dasatinib and uses thereof | Jan 22, 2041 | Handa Therap |
| Phyrago | US11298356 | Amorphous solid dispersions of dasatinib and uses thereof | Jan 22, 2041 | Handa Therap |
| Phyrago | US11324745 | Amorphous solid dispersions of dasatinib and uses thereof | Jan 22, 2041 | Handa Therap |
| Phyrago | US12433891 | Amorphous Solid Dispersions Of Dasatinib And Uses Thereof | Jan 22, 2041 | Handa Therap |
| Phyrago | US12465606 | Amorphous Solid Dispersions Of Dasatinib And Uses Thereof | Jan 22, 2041 | Handa Therap |
| Phyrago | US12544376 | Amorphous Solid Dispersions Of Dasatinib And Uses Thereof | Jan 22, 2041 | Handa Therap |
| Sprycel |
US7491725 (Pediatric) | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
Sep 28, 2026
(Expired) | Bristol Myers Squibb |
| Sprycel | US7491725 | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
Mar 28, 2026
(Expired) | Bristol Myers Squibb |
| Sprycel |
US8680103 (Pediatric) | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
Aug 04, 2025
(Expired) | Bristol Myers Squibb |
| Sprycel | US8680103 | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
Feb 04, 2025
(Expired) | Bristol Myers Squibb |
| Sprycel |
US6596746 (Pediatric) | Cyclic protein tyrosine kinase inhibitors |
Dec 28, 2020
(Expired) | Bristol Myers Squibb |
| Sprycel |
US7153856 (Pediatric) | Cyclic protein tyrosine kinase inhibitors |
Oct 28, 2020
(Expired) | Bristol Myers Squibb |
| Sprycel |
US7125875 (Pediatric) | Cyclic protein tyrosine kinase inhibitors |
Oct 13, 2020
(Expired) | Bristol Myers Squibb |
| Sprycel | US6596746 | Cyclic protein tyrosine kinase inhibitors |
Jun 28, 2020
(Expired) | Bristol Myers Squibb |
| Sprycel | US7153856 | Cyclic protein tyrosine kinase inhibitors |
Apr 28, 2020
(Expired) | Bristol Myers Squibb |
| Sprycel | US7125875 | Cyclic protein tyrosine kinase inhibitors |
Apr 13, 2020
(Expired) | Bristol Myers Squibb |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Dasatinib's patents.
Latest Legal Activities on Dasatinib's Patents
Given below is the list recent legal activities going on the following patents of Dasatinib.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 06 Aug, 2020 | US7491725 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 14 Jun, 2018 | US7153856(Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 12 Apr, 2018 | US7125875 |
| Post Issue Communication - Certificate of Correction | 22 Nov, 2011 | US7491725 |
| Email Notification Critical
| 03 Aug, 2010 | US7491725 |
| Mail-Record a Petition Decision of Granted for Patent Term Adjustment after Allowance | 28 Jul, 2010 | US7491725 |
| Record a Petition Decision of Granted for Patent Term Adjustment after Allowance | 27 Jul, 2010 | US7491725 |
| Adjustment of PTA Calculation by PTO | 27 Jul, 2010 | US7491725 |
| Court Processing Terminated | 23 Jun, 2010 | US7491725 |
| Decision in Civil Action - Dismissed by Court | 23 Jun, 2010 | US7491725 |
Dasatinib's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Dasatinib:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
